2,6-Di-o-methyl-d-mannose | 58859-02-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,6-Di-o-methyl-d-mannose
• 英文别名: (2S,3S,4R,5R)-3,4,5-trihydroxy-2,6-dimethoxyhexanal
• CAS: 58859-02-2
• 化学式: C₈H₁₆O₆
• 分子量: 208.21
• InChiKey: OJBVKTGJVJESJJ-WCTZXXKLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  96.2
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• EXTRACT PRODUCED FROM ORCHID FAMILY PLANT, METHOD FOR PRODUCTION THEREOF, AND PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING EXTRACT PRODUCED FROM ORCHID FAMILY PLANT
  申请人：Nichirei Biosciences Inc.

  公开号：EP2275083A1

  公开（公告）日：2011-01-19

  This invention relates to an extract obtained from a plant of the genus Odontoglossum of the family Orchidaceae, or from a plant derived from a hybrid plant of the genus Odontoglossum and the genus Cochlioda, to a method for preparing the extract, and to an external agent for skin comprising the extract.

  本发明涉及一种从兰科奥杜鹃属植物或从奥杜鹃属与蜗牛属杂交植物中提取的提取物、一种提取物的制备方法以及一种包含提取物的皮肤外用制剂。
• Biosynthesis of everninomicin analogs in Micromonospora carbonacea var aurantiaca
  申请人：VANDERBILT UNIVERSITY

  公开号：US10696996B2

  公开（公告）日：2020-06-30

  Disclosed are methods of preparing everninomicin analogs by genetic alteration of Micromonospora carbonacea. Everninomicin analogs prepared by these methods and methods of using these analogs to treat infections are also disclosed.

  本发明公开了通过改变小孢子虫（Micromonospora carbonacea）的基因来制备 Everninomicin 类似物的方法。还公开了通过这些方法制备的常新霉素类似物以及使用这些类似物治疗感染的方法。
• AVILAMYCIN-DERIVATE
  申请人：Combinature Biopharm AG

  公开号：EP1363924A1

  公开（公告）日：2003-11-26
• BIOSYNTHESIS OF EVERNINOMICIN ANALOGS IN MICROMONOSPORA CARBONACEA VAR AURANTIACA
  申请人：Vanderbilt University

  公开号：EP3387133A1

  公开（公告）日：2018-10-17
• Avilamycin derivatives
  申请人：Combinature Biopharm AG

  公开号：US20040006026A1

  公开（公告）日：2004-01-08

  Avilamycin derivatives, gene technology biosynthesis processes for their production, medications containing these compounds, as well as the use of these compounds for the production of a active agent against infectious diseases, as well as nucleic acids, proteins, and gene clusters and corresponding cells that are connected to the production of these avilamycin derivatives are disclosed.